Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement On December 5, 2025, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Note Purchase
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above under Item 1.
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Note Purchase Agreement, dated December 5, 2025, by and between the Company and L